This article is more than 5 years old. Information may no longer be current.
Beta-blockers still important in glaucoma management
Click Here to Manage Email Alerts
SAN FRANCISCO — Beta-blockers still play an important role in glaucoma treatment because of their cost-effectiveness and once-a-day dosing schedule, according to a speaker here.
Speaking at a function sponsored by Ista Pharmaceuticals, Ehsan Sadri, MD, said that Istalol (timolol) was “a godsend in my practice.” He cited the affordability of the beta-blocking drug for his patients who cannot afford prostaglandin therapy. He also noted that the once-daily instillation aids patient compliance.
The lower systemic absorption that is characteristic of Istalol also means a reduction in cardiovascular effect, he said.
There is also enhanced patient acceptability because the formulation of Istalol causes less blurred vision than other solutions, Dr. Sadri said.